Pfizer's Q1 Update May Mark A Bottom In The Stock (Archive)

This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.

Elevator Pitch

• Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25.
• Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives.
• Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again.
• PFE stock is trading at trough valuations and at a larger-than-usual discount vs peers. So I think there is some decent margin of safety.
• Technical analysis vs SPX500 suggests PFE may be forming a bottom, but strong buyer signals are still absent.

Read the full article here.